Inotersen Sodium is a transthyretin-directed antisense oligonucleotide indicated for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis. By binding to transthyretin… Read more
Inotersen Sodium is a transthyretin-directed antisense oligonucleotide indicated for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis. By binding to transthyretin mRNA, this therapeutic agent inhibits the production of transthyretin protein, thereby reducing the formation of pathogenic amyloid deposits. To support the rigorous analytical requirements of pharmaceutical development and manufacturing, this category includes a comprehensive range of Inotersen Sodium reference standards. These essential tools, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds, are critical for accurate method validation and quality control. Laboratories rely on these high-quality materials to facilitate precise impurity profiling and ensure consistency in the assessment of this complex antisense oligonucleotide, helping to maintain strict regulatory compliance throughout the drug lifecycle.